Endo Y, Tani T, Kawaguchi A, Eguchi Y, Sano H, Kurumi Y, Hanasawa K, Ishibashi H, Terata N, Shibata J
First Dept. of Surgery, Shiga University of Medical Science.
Gan To Kagaku Ryoho. 1993 Aug;20(11):1535-7.
Postoperative adjuvant locoregional chemotherapy was performed on patients who underwent hepatic resection for metastatic colorectal cancer. To prevent recurrence in the residual liver after hepatic resection. 7 patients received intra-hepato-arterial infusion of MMC, 5-fluorouracil (5-FU), doxorubicin + Lipiodol emulsion. Sixteen cases did not receive such treatment. The 1-, 2- and 3-year cumulative disease free rates were 100, 80 and 40% in the patients with this adjuvant chemotherapy, against 61.4, 54.6 and 28.1% in those without this locoregional therapy, respectively. The 1-, 2- and 3-year cumulative survival rates were 100, 100 and 60% in the TAI-E group, and 73.7, 63.3 and 63.3% in the patients without TAI-E, respectively. Postoperative adjuvant locoregional chemotherapy is considered effective to prevent the recurrence of metastatic colorectal cancer in the residual liver after hepatectomy.
对接受转移性结直肠癌肝切除的患者进行术后辅助局部区域化疗，以预防肝切除术后残余肝脏复发。7例患者接受肝动脉内灌注丝裂霉素、5-氟尿嘧啶（5-FU）、阿霉素+碘油乳剂治疗。16例患者未接受此类治疗。接受这种辅助化疗的患者1年、2年和3年的累积无病生存率分别为100%、80%和40%，而未接受这种局部区域治疗的患者分别为61.4%、54.6%和28.1%。TAI-E组1年、2年和3年的累积生存率分别为100%、100%和60%，未接受TAI-E治疗的患者分别为73.7%、63.3%和63.3%。术后辅助局部区域化疗被认为对预防肝切除术后残余肝脏转移性结直肠癌的复发有效。
